全文获取类型
收费全文 | 14120篇 |
免费 | 985篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 118篇 |
儿科学 | 431篇 |
妇产科学 | 447篇 |
基础医学 | 2100篇 |
口腔科学 | 244篇 |
临床医学 | 1807篇 |
内科学 | 2480篇 |
皮肤病学 | 409篇 |
神经病学 | 1368篇 |
特种医学 | 272篇 |
外科学 | 1265篇 |
综合类 | 95篇 |
一般理论 | 38篇 |
预防医学 | 1577篇 |
眼科学 | 237篇 |
药学 | 1040篇 |
中国医学 | 24篇 |
肿瘤学 | 1185篇 |
出版年
2024年 | 14篇 |
2023年 | 141篇 |
2022年 | 328篇 |
2021年 | 551篇 |
2020年 | 277篇 |
2019年 | 492篇 |
2018年 | 518篇 |
2017年 | 355篇 |
2016年 | 458篇 |
2015年 | 437篇 |
2014年 | 613篇 |
2013年 | 771篇 |
2012年 | 1106篇 |
2011年 | 1167篇 |
2010年 | 639篇 |
2009年 | 525篇 |
2008年 | 878篇 |
2007年 | 915篇 |
2006年 | 894篇 |
2005年 | 827篇 |
2004年 | 713篇 |
2003年 | 634篇 |
2002年 | 601篇 |
2001年 | 84篇 |
2000年 | 77篇 |
1999年 | 80篇 |
1998年 | 109篇 |
1997年 | 78篇 |
1996年 | 71篇 |
1995年 | 60篇 |
1994年 | 74篇 |
1993年 | 53篇 |
1992年 | 48篇 |
1991年 | 50篇 |
1990年 | 34篇 |
1989年 | 40篇 |
1988年 | 37篇 |
1987年 | 20篇 |
1986年 | 25篇 |
1985年 | 34篇 |
1984年 | 31篇 |
1983年 | 29篇 |
1982年 | 30篇 |
1981年 | 36篇 |
1980年 | 31篇 |
1979年 | 17篇 |
1978年 | 19篇 |
1977年 | 23篇 |
1976年 | 17篇 |
1974年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. 总被引:30,自引:0,他引:30
Christopher L Corless Arin Schroeder Diana Griffith Ajia Town Laura McGreevey Patina Harrell Sharon Shiraga Troy Bainbridge Jason Morich Michael C Heinrich 《Journal of clinical oncology》2005,23(23):5357-5364
PURPOSE: Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib. A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro. Little is known of the other types of PDGFRA mutations that occur in GISTs. MATERIALS AND METHODS: We determined the KIT and PDGFRA mutation status of 1,105 unique GISTs using a combination of denaturing high-performance liquid chromatography and direct sequencing. RESULTS: 66 in exon 18, 11 in exon 12, and three in exon 14. Transient expression of representative PDGFRA isoforms in CHO cells revealed imatinib sensitivity of exon 12 mutations (SPDHE566-571R and insertion ER561-562) and an exon 14 substitution (N659K). However, most isoforms with a substitution involving codon D842 in exon 18 (D842V, RD841-842KI, DI842-843IM) were resistant to the drug, with the exception of D842Y. Interestingly, other mutations in exon 18 (D846Y, N848K, Y849K and HDSN845-848P) were all imatinib sensitive. Proliferation studies with BA/F3 cell lines stably expressing selected PDGFRA mutant isoforms supported these findings. CONCLUSION: Including our cases, there are 289 reported PDGFRA-mutant GISTs, of which 181 (62.6%) had the imatinib-resistant substitution D842V. However, our findings suggest that more than one third of GISTs with PDGFRA mutations may respond to imatinib and that mutation screening may be helpful in the management of these tumors. 相似文献
122.
Nicholas J Heyer Diana Echeverria Alvah C Bittner Federico M Farin Claire C Garabedian James S Woods 《Toxicological sciences》2004,81(2):354-363
Recent reports have described neurobehavioral impairments in human subjects carrying a V66M polymorphism in the gene encoding brain-derived neurotrophic factor (BDNF). Inasmuch as ventral nervous system (CNS) deficits associated with this BDNF polymorphism are similar to those observed among subjects with chronic exposure to elemental mercury (Hg degrees ), we examined the potential effect of this BDNF polymorphism on symptoms and mood in an established cohort of dental practitioners with chronic low-level Hg degrees exposure. Self-reported symptoms and mood were obtained by computerized questionnaire from 193 male dentists (DTs) and 230 female dental assistants (DAs). Spot urine samples were analyzed for mercury concentrations to evaluate recent exposure. Detailed work histories were obtained to calculate chronic indices of Hg degrees exposure. Buccal cell samples were obtained to identify the V66M polymorphism of BDNF. Scores for 11 current and 12 recent and chronic symptom groups, along with six mood factors, were evaluated with respect to recent and chronic Hg degrees exposure and BDNF polymorphism. Multiple regression analysis controlled for age, race, socioeconomic status, tobacco and alcohol use, self-reported health problems, and medications. Separate evaluations were conducted for DTs and DAs. Twenty-three associations between recent or chronic Hg degrees exposure and BDNF status and self-reported symptoms were observed with p < 0.10. All but three were in the expected direction (symptom scores increasing with Hg degrees exposure or BDNF polymorphism), and all but six were among DAs. All eight correlations between chronic exposure indices and recent and chronic symptoms among DAs were in the expected direction. All seven associations between BDNF and symptoms were in the expected direction and split between DTs and DAs. All three associations with mood factors were among DAs and in the expected direction. These results indicate that among DAs very low levels of occupational Hg degrees exposure are associated with increased symptoms. The BDNF polymorphism is also associated with increased symptom and mood scores. Notably, Hg degrees and BDNF polymorphism were additive with respect to their associations with the same symptom group. 相似文献
123.
Emily Banks Gillian Reeves Valerie Beral Diana Bull Barbara Crossley Moya Simmonds Elizabeth Hilton Stephen Bailey Nigel Barrett Peter Briers Ruth English Alan Jackson Elizabeth Kutt Janet Lavelle Linda Rockall Matthew G Wallis Mary Wilson Julietta Patnick 《British medical journal》2004,328(7451):1291-1292
124.
Alessandro Mussa Kelly A. Duffy Diana Carli Giovanni Battista Ferrero Jennifer M. Kalish 《Pediatric blood & cancer》2019,66(1)
Patients with Beckwith‐Wiedemann spectrum (BWSp) undergo quarterly alpha‐fetoprotein measurement for hepatoblastoma (HB) screening up to 4 years of age, paralleling the epidemiology of nonsyndromic HB. However, specific data on the timing of HB development in BWSp are lacking. Here we compare the timing of presentation of HBs in BWSp with a control cohort of consecutive HB cases, demonstrating that halving screening duration of screening procedures in BWSp likely will not impact its effectiveness. 相似文献
125.
Bria E Gralla RJ Raftopoulos H Cuppone F Milella M Sperduti I Carlini P Terzoli E Cognetti F Giannarelli D 《Lung cancer (Amsterdam, Netherlands)》2009,63(1):50-57
Several randomized trials investigating the benefit of adjuvant chemotherapy after surgery in non-small cell lung cancer (NSCLC) have provided conflicting results. With over 7000 patients included, we analyzed results of 13 reports over the past 10 years in which patients received either platinum-containing chemotherapy or not. The major endpoint was to assess the magnitude of the benefit of adjuvant chemotherapy in terms of the absolute benefit. All phase III randomized trials and meta-analyses published as peer-reviewed papers or as abstracts from 1994 to 2007 were eligible. A literature-based meta-analysis was performed; event-based overall- and disease-free survival (OS/DFS) and Relative Risks (RRs) with 95% confidence intervals (CIs) were derived. Magnitudes of benefit were evaluated with: absolute benefit and the number of patients treated for one patient to benefit. Seven sub-populations were examined. Combined effect estimation was computed with fixed- and random-effect models; a heterogeneity test was also applied. Twelve trials plus an individual patient meta-analysis (7334 patients) were gathered; the trials were designed to determine if cisplatin- or carboplatin-based chemotherapy improves survival over surgery. When data were pooled and plotted, significant differences in favor of chemotherapy were seen in OS in all seven sub-population, with a relative benefit of 7-12% and an absolute benefit ranging from 2.5% to 4.1%. A more significant trend for chemotherapy was found in DFS. No significant heterogeneity was observed for all outcomes and sub-populations. The absolute benefit of adjuvant chemotherapy remains essentially the same regardless of how data are screened. While significant differences are clearly found in this analysis, the small magnitude of benefit seen with this large population, especially when considering the number of patients needed for one to benefit, raises important issues when weighing risks and benefits of treatment for individual patients. 相似文献
126.
Diana Sarfati MBChB MPH PhD Bogda Koczwara BMBS MBioethics Christopher Jackson MBChB 《CA: a cancer journal for clinicians》2016,66(4):337-350
Answer questions and earn CME/CNE Comorbidity is common among cancer patients and, with an aging population, is becoming more so. Comorbidity potentially affects the development, stage at diagnosis, treatment, and outcomes of people with cancer. Despite the intimate relationship between comorbidity and cancer, there is limited consensus on how to record, interpret, or manage comorbidity in the context of cancer, with the result that patients who have comorbidity are less likely to receive treatment with curative intent. Evidence in this area is lacking because of the frequent exclusion of patients with comorbidity from randomized controlled trials. There is evidence that some patients with comorbidity have potentially curative treatment unnecessarily modified, compromising optimal care. Patients with comorbidity have poorer survival, poorer quality of life, and higher health care costs. Strategies to address these issues include improving the evidence base for patients with comorbidity, further development of clinical tools to assist decision making, improved integration and coordination of care, and skill development for clinicians. CA Cancer J Clin 2016;66:337‐350. © 2016 American Cancer Society. 相似文献
127.
林天谱 《世界中医骨伤科杂志》2005,7(2):78-79
背部肌筋膜综合征主要是指因背部肌肉劳损、受凉引起,临床以背痛为主的一组征候群。只要诊断、定位明确,九一针疗法对此具有良好的疗效。 相似文献
128.
Mandelson MT Miglioretti D Newcomb PA Harrison R Potter JD 《Cancer causes & control : CCC》2003,14(10):979-984
INTRODUCTION: Colorectal cancer is the second leading cause of cancer death among US men and women. A number of studies report that hormone replacement therapy (HRT) reduces the risk of colorectal cancer, but fewer studies have examined the relation between HRT use and survival after diagnosis and none examined this relation by anatomic location of the primary colon tumor. METHODS: Data from a cohort of 699 women 50-79 years of age diagnosed with colon cancer between 1980 and 1998 in a large Health Maintenance Organization based in Seattle, Washington were analyzed to examine the relation between HRT use prior to diagnosis and survival. Use of HRT was ascertained from a computerized pharmacy database. RESULTS: HRT use was associated with a 41% reduction in risk of death after adjustment for age, stage, and diagnosis year (p= 0.037). The association between HRT use and colon cancer survival was strongest among women with cancer in the distal colon (hazard rate ratio 0.33, 95% confidence interval, 95% CI: 0.13-0.83), while little or no association between HRT use and survival was observed among women with proximal tumors (HRR 0.78, 95% CI: 0.42-1.44). CONCLUSIONS: These findings suggest that HRT use is associated with improved survival from colon cancer. Future observational and laboratory studies should shed light on how hormones may be related to reduced incidence and improved prognosis. 相似文献
129.
Brian L Sprague Amy Trentham-Dietz Curtis J Hedman Jue Wang Jocelyn DC Hemming John M Hampton Diana SM Buist Erin J Aiello Bowles Gale S Sisney Elizabeth S Burnside 《Breast cancer research : BCR》2013,15(3):R45
Introduction
Humans are widely exposed to estrogenically active phthalates, parabens, and phenols, raising concerns about potential effects on breast tissue and breast cancer risk. We sought to determine the association of circulating serum levels of these chemicals (reflecting recent exposure) with mammographic breast density (a marker of breast cancer risk).Methods
We recruited postmenopausal women aged 55 to 70 years from mammography clinics in Madison, Wisconsin (N = 264). Subjects completed a questionnaire and provided a blood sample that was analyzed for mono-ethyl phthalate, mono-butyl phthalate, mono-benzyl phthalate, butyl paraben, propyl paraben, octylphenol, nonylphenol, and bisphenol A (BPA). Percentage breast density was measured from mammograms by using a computer-assisted thresholding method.Results
Serum BPA was positively associated with mammographic breast density after adjusting for age, body mass index, and other potentially confounding factors. Mean percentage density was 12.6% (95% confidence interval (CI), 11.4 to 14.0) among the 193 women with nondetectable BPA levels, 13.7% (95% CI, 10.7 to 17.1) among the 35 women with detectable levels below the median (<0.55 ng/ml), and 17.6% (95% CI, 14.1 to 21.5) among the 34 women with detectable levels above the median (>0.55 ng/ml; Ptrend = 0.01). Percentage breast density was also elevated (18.2%; 95% CI, 13.4 to 23.7) among the 18 women with serum mono-ethyl phthalate above the median detected level (>3.77 ng/ml) compared with women with nondetectable BPA levels (13.1%; 95% CI, 11.9 to 14.3; Ptrend = 0.07). No other chemicals demonstrated associations with percentage breast density.Conclusions
Postmenopausal women with high serum levels of BPA and mono-ethyl phthalate had elevated breast density. Further investigation of the impact of BPA and mono-ethyl phthalate on breast cancer risk by using repeated serum measurements or other markers of xenoestrogen exposure are needed. 相似文献130.
Laila M. Sherief Elhamy Rifky Mohamed Attia Reda Ahmed Naglaa M. Kamal Mohammed A. M. Oshi Diana Hanna 《Medicine》2022,101(45)
Hearing damage is one of the main toxic effects of platinum compounds, it derives from the irreversible degeneration of hair cells of the ear. Genetic association studies have suggested an association between GSTP1 c.313A>G variant and platinum-induced ototoxicity in childhood cancer survivors. We aimed to detect the frequency of ototoxicity and associated risk factors in survivors of childhood cancer receiving platinum-based chemotherapy and to detect the relation between GSTP1 c.313A>G (rs1695) polymorphisms and ototoxicity. We conducted a cross-sectional study on 64 cancer survivors who received platinum agents (cisplatin and/or carboplatin) at least 2 years after the end of chemotherapy. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GSTP1 c.313A>G polymorphisms. Hearing loss (HL) was identified in 16/64 patients (25%), including 62.5% treated with cisplatin and 37.5% treated with carboplatin. The greater incidence of ototoxicity was found in children treated for osteosarcoma (28.1%) followed by patients with germ cell tumors (25%) and neuroblastoma (21.9%). The AA, AG, and GG types of GSTP1 c.313A>G variant were detected in 84.4%, 9.4%, and 6.3%, respectively, of patients with HL with a significant association between mutant genotype of GSTP1 rs1695 and platinum-induced ototoxicity (P = .035). HL was not significantly associated with the total cumulative dose of cisplatin and carboplatin. GSTP1 c.313A>G variant may increase the risk of HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy. 相似文献